| 摘要: |
| ［摘要］ 目的 探讨TP方案与IP方案在非小细胞肺癌治疗中的应用效果。方法 将136例非小细胞肺癌患者采用随机数字表法分为TP组68例和IP组68例，TP组予紫杉醇+顺铂治疗，IP组予伊立替康+顺铂治疗，21 d为1个周期，治疗3个周期。结果 TP组完全缓解（CR）16例，部分缓解（PR）15例，稳定（SD）22例，进展（PD）15例，IP组依次为17、13、25、13例，两组临床疗效比较差异无统计学意义（P>0.05）；TP组和IP组的不良反应主要为血液系统毒性，两组比较差异无统计学意义（P>0.05）。结论 TP方案与IP方案治疗非小细胞肺癌临床疗效确切，有效率和安全性均较好，无明显差异，应根据患者特点个体化选择化疗方案。 |
| 关键词: 紫杉醇 伊立替康 非小细胞肺癌 |
| DOI：10.3969/j.issn.1674-3806.2014.09.13 |
| 分类号:R 734 |
| 基金项目: |
|
| Comparison of the effects of TP and IP regimen in the treatment of non small cell lung cancer |
|
FENG Wen-shuai
|
|
Department of Respiratory and Critical Diseases, the People′s Hospital of Gongyi City, Henan 451200, China
|
| Abstract: |
| ［Abstract］ Objective To study the application effect of TP regimen and IP regimen in the treatment of non small cell lung cancer.Methods One huerdred and thirty-six patients with non small cell lung cancer were randomly divided into TP group（n=68） and IP group（n=68).TP group was treated with paclitaxel plus cisplatin, IP group was treated with irinotecan plus cisplatin, 21 days for 1 cycle for 3 cycles.Results In TP group, there was CR16 cases, PR15 cases, SD22 cases, PD15 cases, In IP group there was 17, 13, 25, 13 cases respectively.There was no statistically significant difference in clinical efficacy before two groups(P>0.05), the main side effects in TP group and IP group was the blood system toxicity, there was no significant difference between two groups(P>0.05).Conclusion TP and IP regimen in the treatment of non small cell lung cancer have precise clinical efficacy, better efficacy and safety.There was no obvious difference between two groups,and it is necessary to chose the chemotherapy regimens according to the characteristics of individual patient. |
| Key words: Paclitaxel Irinotecan Non small cell lung cancer |
